Name (Synonyms) | Correlation | |
---|---|---|
drug727 | Complex diagnostic panel Wiki | 1.00 |
drug3100 | WFI water nebulization Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
COVID-19 is causing a serious viral pandemic in terms of health and social impact. To date, no treatment has yet demonstrated its efficacy in treating the infectious disease (COVID-19). Pulmonary administration of Interferon (IFN) type I is a therapeutic strategy with high potential,due to higher local concentrations and minimal adverse effects. Type I interferons (including IFN-α and IFN-β) are antiviral defence cytokines and also have the potential to negatively modulate IFN Type II and IL-6 dependent cytokine storm, the latter being induced in the late forms of COVID-19. In vitro, IFN-β were more effective on COVID-19 than IFN-α. In existing preliminary studies, only patients receiving IFN type I modulators have a decrease in viral carriage and a rapid reversal. The purpose of this project is to assess in hospitalized patients with oxygen for COVID 19, the clinical efficacy on oxygen requirements of the addition of inhaled Interferon type I compared to the control arm .
Description: oxygen requirement score at day 0
Measure: oxygen requirement score at day 0 Time: day 0Description: oxygen requirement score at day 15
Measure: oxygen requirement score at day 15 Time: day 15Description: Variation oxygen requirement score between day 0 and day15
Measure: Variation oxygen requirement score between day 0 and day15 Time: at day 15